RTA is an investigational multi-receptor peptide agonist that interacts with the GLP-1, GIP, and glucagon receptor families. It is being studied for its ability to modulate multiple metabolic pathways simultaneously, allowing researchers to explore combined incretin–glucagon signaling mechanisms.
Because it engages three receptor systems involved in glucose regulation, lipid metabolism, energy balance, and gastrointestinal signaling, Retatrutide provides a model for evaluating how coordinated receptor activation may influence metabolic processes.

Mechanisms of Action
(Summaries based on published scientific literature — not effects of this product.)

• GLP-1 Receptor Interaction: Engages the GLP-1 receptor to influence glucose-dependent insulin signaling, gastrointestinal motility, and central appetite-related pathways.
• GIP Receptor Interaction: Modulates the GIP receptor, which is involved in nutrient-responsive insulin secretion and lipid metabolism research.
• Glucagon Receptor Interaction: Activates hepatic glucagon receptors, enabling the study of pathways related to energy expenditure, hepatic glucose output, and fatty-acid oxidation.
• Triple-Receptor Signaling Model: Combines incretin and glucagon pathway activation, allowing researchers to investigate metabolic network interactions not achievable through single-receptor agonists.